Yohei Morishita
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yohei Morishita has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Kazuto Matsuura
Department of Head and Neck Surgery, National Cancer Center Hospital East, Chiba, Japan
2 shared publicationsRyuichi Hayashi
Department of Head and Neck Surgery, National Cancer Center Hospital East, Chiba, Japan
2 shared publicationsTakeshi Shinozaki
Department of Head and Neck Surgery, National Cancer Center Hospital East, Chiba, Japan
2 shared publicationsToshifumi Tomioka
Department of Head and Neck Surgery, National Cancer Center Hospital East, Chiba, Japan
2 shared publicationsWataru Okano
Department of Head and Neck Surgery, National Cancer Center Hospital East, Chiba, Japan
2 shared publications- Hirofumi Kuno
Department of Diagnostic Radiology, National Cancer Center Hospital East, Kashiwa, Japan
1 shared publication
Latest Publications
- 1 February 2023
- Published by Elsevier in Auris Nasus Larynx
- Vol. 50 (1) , 151-155
Human papillomavirus-related multiphenotypic sinonasal carcinoma
- 1 February 2023
- Published by Elsevier in Auris Nasus Larynx
- Vol. 50 (1) , 151-155
Human papillomavirus-related multiphenotypic sinonasal carcinoma
- 26 March 2022
- Published by Elsevier in Auris Nasus Larynx
- Vol. 49 (5) , 856-861
Is elective neck dissection necessary for patients with cT3-4N0 parotid gland cancer?
- 26 March 2022
- Published by Elsevier in Auris Nasus Larynx
- Vol. 49 (5) , 856-861
Is elective neck dissection necessary for patients with cT3-4N0 parotid gland cancer?
- Open Access
- 25 November 2021
- Published by Springer Nature in International Cancer Conference Journal
- Vol. 11 (1) , 71-74
A case of Epstein–Barr virus-positive mucocutaneous ulcer of the hypopharynx: a mimicker of hypopharyngeal squamous cell carcinoma
Epstein–Barr virus-positive mucocutaneous ulcer (EBVMCU) is a new disease, described by the World Health Organization in 2017. It has been recognized as a specific type of immunodeficiency-associated lymphoproliferative disorder. Since patients with EBVMCU present with only cutaneous or mucosal ulcers, it is difficult to clinically distinguish them from carcinoma. A 72-year-old man, who took methotrexate (MTX) (12 mg/week) for rheumatoid arthritis, was referred to our hospital because endoscopy revealed an ulcerated mass in the left pyriform sinus, suggesting hypopharyngeal squamous cell carcinoma. Contrast-enhanced computed tomography and magnetic resonance imaging revealed an ill-defined mass in the left pyriform sinus without lymphadenopathy in the head and neck region. A biopsy of the ulcerative lesion in the hypopharynx was performed, and lymphoproliferative disease was suspected, based on the histopathological findings. Two weeks after MTX withdrawal, the lesions in the hypopharynx disappeared. The patient was diagnosed with EBVMCU, based on the clinical and histopathological findings. This is the first case report of EBVMCU of the hypopharynx. EBVMCU should be considered as a differential diagnosis in immunocompromised patients with hypopharyngeal mucosal ulcers without lymph node or organ involvement.
- 25 November 2021
- Published by Springer Nature in International Cancer Conference Journal
- Vol. 11 (1) , 71-74
Open AccessA case of Epstein–Barr virus-positive mucocutaneous ulcer of the hypopharynx: a mimicker of hypopharyngeal squamous cell carcinoma
Epstein–Barr virus-positive mucocutaneous ulcer (EBVMCU) is a new disease, described by the World Health Organization in 2017. It has been recognized as a specific type of immunodeficiency-associated lymphoproliferative disorder. Since patients with EBVMCU present with only cutaneous or mucosal ulcers, it is difficult to clinically distinguish them from carcinoma. A 72-year-old man, who took methotrexate (MTX) (12 mg/week) for rheumatoid arthritis, was referred to our hospital because endoscopy revealed an ulcerated mass in the left pyriform sinus, suggesting hypopharyngeal squamous cell carcinoma. Contrast-enhanced computed tomography and magnetic resonance imaging revealed an ill-defined mass in the left pyriform sinus without lymphadenopathy in the head and neck region. A biopsy of the ulcerative lesion in the hypopharynx was performed, and lymphoproliferative disease was suspected, based on the histopathological findings. Two weeks after MTX withdrawal, the lesions in the hypopharynx disappeared. The patient was diagnosed with EBVMCU, based on the clinical and histopathological findings. This is the first case report of EBVMCU of the hypopharynx. EBVMCU should be considered as a differential diagnosis in immunocompromised patients with hypopharyngeal mucosal ulcers without lymph node or organ involvement.